Congress funds research into why thyroid disease goes undiagnosed in women and minorities
H.R. 6897 — Thyroid Disease CARE Act of 2025 · Filed by Haley Stevens (D-MI) · 1 cosponsor · Introduced Dec 18, 2025 · Referred to committee
Your members of Congress
Enter a ZIP to see where your representative and both senators stood on this bill.
Looked up on this device — your ZIP is never stored on our servers.
What it does
This bill directs the Department of Health and Human Services to conduct research on thyroid disease, analyze disparities in diagnosis and treatment across racial, ethnic, gender, and socioeconomic groups, and run a public awareness campaign about thyroid disease symptoms and treatment options. It authorizes $30 million annually for research, $30 million annually for disparity analysis, and $3 million annually for public awareness through 2030.
Why we flagged it
The bill is a straightforward public health authorization that funds research, disparity analysis, and awareness campaigns for thyroid disease. It contains no regulatory changes, tax provisions, or industry carve-outs—only appropriations for HHS to conduct evidence-gathering and education activities.
What the text implies
- By mandating analysis of disparities in thyroid disease diagnosis and treatment, the bill may expose systemic gaps in how thyroid conditions are recognized and managed in underserved communities, potentially creating political pressure for insurance coverage or clinical practice changes.
- The requirement to collect data from private health insurers and Medicaid programs may reveal cost-sharing barriers that prevent patients from accessing thyroid treatments, which could inform future coverage mandates or policy debates.
The full analysis lists 3 implications of this text.
Who stands to gain
National Institutes of Health (research funding); Academic medical centers and research institutions; Nonprofit health organizations and patient advocacy groups